Retatrutide: what the Phase 2 trials measured, what Phase 3 is testing, and what the noise gets wrong.

The short version

Retatrutide is an experimental drug developed by Eli Lilly. It is not approved by the FDA or any other regulator. You cannot get a prescription for it. It is currently being tested in large clinical trials — the TRIUMPH program — and no results from those trials have been published yet.

What has been published: a 48-week Phase 2 trial that enrolled 338 people with obesity and found that the highest dose studied produced an average 24.2% reduction in body weight. That is a larger number than earlier weight-loss drugs achieved. It is a trial result, not a guarantee.

Retatrutide works by activating three hormone receptors at once — GIP, GLP-1, and glucagon (a glucagon-like peptide-1 receptor agonist is sometimes called a "GLP-1" drug; retatrutide is a triple agonist, not a GLP-3, because there is no GLP-3 receptor). The third arm — glucagon — is the one that pushes energy expenditure up, which is the mechanistic reason researchers think it outperforms dual-agonist drugs.

This site documents what the published trials have found, names the safety signals clearly, and separates the peer-reviewed record from the gray-market claims that surround it. Retatrutide effects and what people report — including the downsides — are on the effects page.

What the Phase 2 record established

Retatrutide has been through Phase 1 and two Phase 2 trials — one in obesity, one in type 2 diabetes — plus a Phase 2a sub-study in metabolic liver disease (MASLD). The headline numbers are real and they are large.

In the 48-week obesity trial, 338 adults received once-weekly subcutaneous injections at doses of 1, 4, 8, or 12 mg, or placebo. At 12 mg, mean body-weight change was -24.2% versus -2.1% with placebo ^[1]. In the type 2 diabetes trial, 12 mg lowered HbA1c (glycated hemoglobin — the standard three-month blood-sugar average) by -2.02% at 24 weeks and body weight by -16.94% at 36 weeks versus -0.01% and -3.00% with placebo ^[2]. In the MASLD sub-study, 12 mg reduced liver fat by -82.4% at 24 weeks, with 86% of participants reaching normal liver fat levels (below 5% by MRI-PDFF — a non-invasive scan that measures the fat fraction in liver tissue) ^[5].

Phase 1b established the pharmacokinetics: a half-life of approximately 6 days supporting once-weekly dosing; at the highest dose in that study, participants lost 8.96 kg (placebo-adjusted) over 12 weeks ^[4].

None of these trials were designed to confirm long-term cardiovascular or kidney outcomes. Those trials are ongoing. The evidence base is substantial for a Phase 2 compound. It is not the evidence base of an approved drug.

What does retatrutide do

Retatrutide is a single synthetic peptide (39 amino acids, built on a GIP backbone) that simultaneously activates three receptor systems: GLP-1R (glucagon-like peptide-1 receptor — suppresses appetite and improves glucose-dependent insulin secretion), GIPR (glucose-dependent insulinotropic polypeptide receptor — reinforces insulin release and influences fat tissue), and GCGR (glucagon receptor — raises energy expenditure and mobilizes hepatic fats) ^[3].

Cryo-EM structural analysis confirmed the triple engagement at atomic resolution: retatrutide is approximately 8.9 times more potent at GIPR than native GIP, while being 0.3x at GCGR and 0.4x at GLP-1R relative to their native hormones ^[3]. The relative selectivity profile — high GIPR potency, moderate GLP-1R and glucagon activity — is what distinguishes retatrutide from earlier single or dual agonists.

A 2025 review positioned the combination as a mechanistic step-change: GLP-1 and GIP suppress appetite and glucose, glucagon adds an energy-expenditure lever that the others lack, and the net effect in trials is larger weight loss than dual-agonist drugs achieved in comparable populations ^[6].

Where the record ends and the noise begins

The domain name has "legit" in it for a reason. A gray market for research-labeled retatrutide material exists online. The FDA issued over 50 warning letters to retatrutide vendors in 2025 for violating the Federal FD&C Act. Gray-market vials are unregulated: identity, purity, and sterility cannot be confirmed. The investigational compound in a Phase 3 trial is not the same object as a vial sold through an unregulated channel with no oversight.

Retatrutide availability as a prescription product does not exist as of 2026. The TRIUMPH Phase 3 program is ongoing. Regulatory applications, if filed, come after Phase 3 data are in — not before.

This site carries no links to vendors, no pricing, no sourcing information. The Retatrutide research section documents the published trial record. The retatrutide results page walks through the endpoint data from the completed Phase 2 trials. That is the scope.

Is retatrutide fda approved

No. Retatrutide is not FDA-approved and is not approved by any regulator as of 2026. It is investigational — classified under active Phase 3 development by Eli Lilly. The TRIUMPH trial program is evaluating obesity, type 2 diabetes, cardiovascular outcomes, and kidney function outcomes; results are pending. Until Phase 3 data are published and reviewed, there is no approved indication, no approved dose, and no authorized prescriber access outside of enrolled clinical trial participants.